Product Description
The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01137019)
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Biosensors Europe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Myocardial Ischemia|Coronary Artery Disease|Myocardial Infarction|ST Elevation Myocardial Infarction|Acute Coronary Syndrome|Stroke|Thrombosis|Inflammation|Angina, Stable|Hypertension|Dyslipidemia
Phase 3: Myocardial Ischemia|Coronary Artery Disease|Coronary Disease
Phase 2: Coronary Thrombosis|ST Elevation Myocardial Infarction|Coronary Artery Disease|Myocardial Ischemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2024-02-008-H01 | N/A |
Not yet recruiting |
Coronary Disease |
2027-05-23 |
|
LEADERS FREE IV (RCT) | N/A |
Not yet recruiting |
Angina, Unstable|Angina, Stable|Angina Pectoris|Coronary Artery Disease|Acute Coronary Syndrome|Myocardial Ischemia |
2026-08-01 |
|
ChiCTR2000041438 | N/A |
Recruiting |
Coronary Disease |
2025-12-31 |
|
JW-PM-DCB-2024 | N/A |
Not yet recruiting |
Coronary Artery Disease|Myocardial Ischemia |
2025-12-30 |